Taking stock of the drug industry, from the lab to the medicine chestJanuary 5, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Charlie Neibergall/AP Biden's FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit? The approval of Florida's plan to import Canadian drugs is expected to set in motion legal battles and a political fight for credit. By John Wilkerson STAT+ | GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients Patients, pharmacies, and insurers scramble to adapt as GSK protects profits by discontinuing Flovent brand name while authorizing a generic inhaler. By Annalisa Merelli Opinion: I went on a mind-boggling journey to get my son's ADHD medication covered by insurance — twice U.S. insurers employ a secretive and complicated process for deciding what drugs to cover. Here's what I learned about fighting back. By Craig Idlebrook Joe Raedle/Getty Images Opinion: The misguided reason why providers aren't prescribing more buprenorphine for opioid use disorder Despite providers' fears about diversion, non-prescribed buprenorphine could be considered a harm reduction measure. By Joëlla W. Adams STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments